Merck’s grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

da | postato in: Senza categoria | 0

An all-oral regimen of
grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without
ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates
for treatment-naive and treatment-experienced people with genotype 1 hepatitis
C virus (HCV), including people with liver cirrhosis and HIV and HCV co-infection,
researchers reported on Tuesday at
the American Association for the